Abstract
Currently available non-invasive prenatal testing (NIPT) assays for fetal red cell and platelet antigens has shown clinical benefit in the management of at-risk pregnancies. However, the capacity for NIPT to predict the full range of antigens with clinically-significant maternal antibodies remains.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
